Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 2, 2025Clinical & Experimental AllergyOpen Access

Real‐World Effectiveness and Safety of JAK Inhibitors in Atopic Dermatitis: A Systematic Review and Meta‐Analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

YKY.H. KimGwangju Institute of Science and TechnologyGSGayeong SeoJKJacob J.E. KoopmanDutch Cancer Society

Discussion

Loading...

Member takes

Overview

Systematic review evaluates effectiveness and safety of JAK inhibitors in atopic dermatitis, indicating real-world outcomes align with clinical trials.

Key Points

  • Core contribution reveals that JAK inhibitors demonstrate effectiveness in treating moderate to severe atopic dermatitis.
  • Data shows pooled effectiveness estimates of EASI-75 reaching 86% at 52 weeks, indicating strong treatment response.
  • Systematic review included 50 studies from real-world settings assessing JAK inhibitors' safety and effectiveness.
  • Findings suggest that real-world efficiency of JAK inhibitors is comparable to results obtained from clinical trials.

Cite This Study

Kim et al. (2025) studied this question.

synapsesocial.com/papers/689a0c72e6551bb0af8d0420https://doi.org/10.1111/cea.70125
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Randomised controlled trials – the gold standard for effectiveness research2018 · 1,654 citations
  2. 2Sample size of 12 per group rule of thumb for a pilot study2005 · 3,215 citations
  3. 3Upadacitinib effectiveness in moderate‐to‐severe atopic dermatitis: A real‐life multicentre and retrospective study2023 · 14 citations
  4. 4The Eczema Area and Severity Index—A Practical Guide2022 · 208 citations
  5. 5Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry2024 · 51 citations